AlphAIAlphAI — Financial news for AI agents
stocktitan.net$ZTS

Zoetis Announces Third Quarter 2026 Results; Highlights Progress Advancing Innovation Across Diversified Portfolio and Narrows Full Year 2026 Revenue Guidance, Raises Full Year 2026 Adjusted EPS Guidance

Zoetis reported Q3 2026 revenue of $2.4B, down 1% YoY, with U.S. revenue down 6% and international up 4%. Adjusted EPS rose 3% to $1.75. The company narrowed FY 2026 revenue guidance to $9.22B-$9.32B but raised adjusted EPS guidance to $6.25-$6.35. Zoetis highlighted progress in its innovation pipeline and product approvals.

Original reporting
stocktitan.net
Published Nov 5, 2026, 12:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 5, 2026, 12:03 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefEarnings
Primary signal
$ZTS
Neutral
high confidence
Mentioned
$ZTS
Relevance
9/10
AlphAI data visualization · based on stocktitan.net
Decision brief

The 30-second read

$ZTSNeutralHigh
01

Why it matters

The earnings release provides fresh data on revenue trends and guidance, influencing trader decisions on ZTS.

02

Market read

ZTS earnings and guidance update are material for investors and can drive short-term price movement.

03

What to watch

Livestock and diagnostics growth may offset companion animal weakness over the longer term.

Relevance 9/10Novelty 9/10Timing: immediate today

Background

Zoetis is the leading animal health company, reporting quarterly results and updating its FY 2026 outlook.

Company-level read

Ticker impact

$ZTSNeutralHigh confidence
Context

Zoetis released Q3 2026 results showing revenue decline but raised full-year revenue and EPS guidance.

Expected impact

likely modest downside pressure as investors weigh revenue decline against improved guidance

Evidence & confidence

The earnings release is the first report of the numbers; the mixed results create uncertainty, leading to a balanced impact.

Market effects

Sector

Animal health sector may see broader scrutiny as Zoetis' revenue miss highlights pressure in companion animal segment.

Regional

U.S. biotech and pharma stocks could experience slight volatility following the mixed earnings.

Global

Limited to investors focused on animal health and related biotech exposures.

Counterpoint

What could challenge this read

Guidance raise suggests underlying strength; the stock could rally on optimism despite the revenue dip.

Key entities

  • Company
    Zoetis

    World's leading animal health company.

  • Executive
    Kristin Peck

    CEO of Zoetis, quoted in the release.

Read at source← All news

StoryZoetis reports Q3 2026 results, beats EPS and raises full‑year guidance

Also covered by

5 outlets

Related articles

$ZTSMedAI 8/10

Zoetis (ZTS) Q3 2026 Earnings Call Transcript

Zoetis (ZTS) reported Q3 2026 earnings with revenue and adjusted net income declining as expected. The company cited challenges in pet care due to rising costs and changing pet ownership trends, while livestock demand remains strong. Zoetis narrowed its full-year revenue guidance to the high end of its range and highlighted investments in key franchises and innovation.

finance.yahoo.com
$ZTSMedAI 8/10

Zoetis 3Q 2026: Revenue $2.39B, EPS $1.44 — 10-Q Summary

Zoetis reported 3Q 2026 revenue of $2.39B, down 1% YoY, and net income of $1.44B, down 18%. Declines were driven by softer U.S. companion-animal demand, competition, and lower prices, partially offset by livestock growth and favorable exchange rates. Higher restructuring costs also impacted earnings. U.S. companion-animal revenue fell 8%, while U.S. livestock and international revenues rose 5% and 4%, respectively.

tradingview.com
$ZTSHighAI 8/10

Why is Zoetis stock climbing today?

Zoetis (ZTS) stock rose 2.4% premarket after Q3 2026 earnings beat estimates, with adjusted EPS of $1.75 vs. $1.51 and revenue of $2.4B vs. $2.3B. The company raised full-year EPS guidance to $6.25–$6.35. International sales grew 4%, while U.S. companion animal business faced challenges. The stock traded near $91.30 premarket, below its 52-week high of $132.49.

investing.com